摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-fluorobenzyl)-7-bromo-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide | 1383785-71-4

中文名称
——
中文别名
——
英文名称
N-(4-fluorobenzyl)-7-bromo-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
英文别名
N-(4-fluorobenzyl)-7-bromo-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisociuinolinc-4-carboxamide;7-bromo-N-[(4-fluorophenyl)methyl]-2-hydroxy-1,3-dioxo-4H-isoquinoline-4-carboxamide
N-(4-fluorobenzyl)-7-bromo-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide化学式
CAS
1383785-71-4
化学式
C17H12BrFN2O4
mdl
——
分子量
407.196
InChiKey
JZTZUYBNGPNGBR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    170-171 °C
  • 密度:
    1.707±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    86.7
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    尼达尼布杂质82 在 氢溴酸三氯化硼 、 potassium hydroxide 、 sodium nitrite 作用下, 以 甲醇二氯甲烷甲苯 为溶剂, 反应 13.17h, 生成 N-(4-fluorobenzyl)-7-bromo-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
    参考文献:
    名称:
    Investigation of a Novel Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Human Immunodeficiency Virus Type 1 Integrase Inhibitors
    摘要:
    We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.
    DOI:
    10.1021/jm500109z
点击查看最新优质反应信息

文献信息

  • [EN] 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS<br/>[FR] 2 -HYDROXYISOQUINOLINE- 1, 3 ( 2H, 4H) - DIONES ET COMPOSÉS ASSOCIÉS SERVANT D'INHIBITEURS DE LA RÉPLICATION DU VIH
    申请人:UNIV LEUVEN KATH
    公开号:WO2012085003A1
    公开(公告)日:2012-06-28
    The present invention relates to compounds and compositions acting as inhibitors of HIV integrase. The compound of the invention is of Formula (I), or a tautomer (I') thereof, or a pharmaceutically acceptable salt, or solvate of said compound or tautomer thereof, wherein R1, R2, R3, R4, R5 and R6 have defined meanings.
    本发明涉及作为HIV整合酶抑制剂的化合物和组合物。该发明的化合物为式(I)的化合物,或其互变异构体(I'),或所述化合物或其互变异构体的药用可接受盐或溶剂,其中R1、R2、R3、R4、R5和R6具有定义的含义。
  • Investigation of a Novel Series of 2-Hydroxyisoquinoline-1,3(2<i>H</i>,4<i>H</i>)-diones as Human Immunodeficiency Virus Type 1 Integrase Inhibitors
    作者:Virginie Suchaud、Fabrice Bailly、Cedric Lion、Christina Calmels、Marie-Line Andréola、Frauke Christ、Zeger Debyser、Philippe Cotelle
    DOI:10.1021/jm500109z
    日期:2014.6.12
    We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.
查看更多